This is available for free at the following address, but they want your email address. I have downloaded it, but I don’t think it is fair to simply republish it. It is big at about 65Mb, but that’s because there are lots of images rather than lots of information. On balance it is worth getting if you have the time to read it.
However, publishing an AI summary is OK:
ClaudeSonnet5paid: (I am coming to my weekly credit limit on Astra which uses a lot of credits)
Now let me read through the key sections in detail.Let me continue through the capital/business, science, and looking-ahead sections.Now let me check the methodology and references sections to complete the picture.# The Longevity Review 2026 (BCG × Super Human) — Summary, Novelty, and Critique
What the document is
This is the inaugural edition of The Longevity Review, an 85-page landscape report jointly produced by Boston Consulting Group (BCG) and Super Human Network (a longevity-focused media/brand distribution company). It is not a primary research paper — it is a synthesis document combining a literature review, PitchBook/Dealroom funding data, a BCG-run consumer survey (n=9,350 across 19 countries), and interviews with roughly a dozen prominent longevity figures (Barzilai, Sinclair, de Grey, Verdin, Betts-LaCroix, Longo, Spector, Maier, Justice, Shlain, and others).
Summary
- Framing: Longevity is split into two goals — compressing the “healthspan gap” (years lived in decline) versus raising the maximum lifespan ceiling. Global life expectancy rose from 67 to 73 years (2000–2019), but the healthspan gap widened from 8.5 to 9.6 years, driven mostly by chronic disease accumulation rather than any real movement in maximum lifespan.
- Drivers framework: Six drivers shape outcomes — nutrition, sleep, exercise, stress/mental health, community, and underlying biology/medical state — surrounded by five emerging commercial “enabler” verticals (diagnostics, tracking/coaching, supplements, pharma/biotech, and infrastructure).
- State of the field: Convergence of demographic pressure, scientific consolidation (the “hallmarks of aging” framework), AI-driven acceleration, and capital (roughly 1,300 companies, over $21 billion cumulative investment, annual deal value up from under $600 million in 2016 to over $4 billion in 2025) has moved longevity from fringe to mainstream. Public interest has scaled faster than actual behavior change — a pattern the report calls the “longevity paradox.”
- Science: The hallmarks-of-aging framework, epigenetic clocks, and early partial-reprogramming results are presented as the field’s key consolidating advances. Four repurposed drug classes (metformin, SGLT2 inhibitors, bisphosphonates, GLP-1 agonists) are cited as the furthest along, though none are approved for aging itself.
- Looking ahead: A three-horizon structure — near term (execution on known lifestyle basics), medium term (the “translation test” of turning biomarkers into regulator-accepted endpoints), and long term (the “rejuvenation frontier” of cellular reprogramming, epigenetic editing, and tissue replacement). Expert predictions for 2050 span from modest 5–10 year gains to Aubrey de Grey’s “longevity escape velocity.”
- Methodology: Explicitly panoramic rather than deep; later editions are promised to cover individual themes (nutrition, AI, pharma, etc.) in more depth.
Novelty
The report’s originality lies almost entirely in synthesis and market packaging, not new science:
- Genuinely original contributions: the BCG Global Study on Longevity survey data (particularly the “longevity paradox” finding that people delay healthy-aging action until they’re already older or already ill, and the generational gap in food literacy) and the proprietary aggregation of PitchBook/Dealroom funding data into a single market-sizing narrative are the closest things to new empirical output.
- Not novel: the six-drivers model, the hallmarks-of-aging framework, the near/medium/long-term horizon structure, and the scientific claims about reprogramming, GLP-1s, and biomarkers are all restatements of existing peer-reviewed literature and existing public commentary from the interviewed experts (many of whom have made these same points in their own books, talks, and papers elsewhere). No new experimental data, mechanism, or hypothesis is introduced.
- In effect, this is a well-referenced trend report aimed at investors, brands, and health-system decision-makers, not a scientific advance.
Critique
- Commercial framing and conflicts of interest: the report is co-authored by a strategy consultancy (BCG) and a company whose stated business is “connecting science and brands to a highly-engaged audience” — i.e., longevity marketing infrastructure. Both organizations have a direct commercial interest in depicting the field as large, credible, and rapidly maturing. Market-sizing numbers and momentum language should be read with that incentive in mind.
- Selective expert panel: the interviewees are a small, self-selected group of high-profile advocates, several of whom run longevity companies or clinics discussed favorably elsewhere in the report (e.g., Sinclair’s reprogramming work, Betts-LaCroix’s Retro Biosciences, Kapp’s Fountain Life). Aubrey de Grey’s “escape velocity” framing and Sinclair’s claim that whole-body human rejuvenation “should be achievable by 2040” are presented as one end of a legitimate expert range, without engaging mainstream biogerontological skepticism toward either claim. The report notes interviewees aren’t meant to imply consensus, but doesn’t include voices who are skeptical of the field’s pace or claims.
- Headline numbers outrun their own caveats: the methodology section admits company/funding figures are “directional rather than exhaustive” and dependent on keyword tagging, and that the 120–150 year “biological ceiling” is “actively debated” — yet these figures appear unqualified in the executive summary, where most readers will stop.
- Correlational lifestyle claims read as near-causal: the “7–10 additional disease-free years” from five lifestyle factors is drawn from cohort data, and the report itself later concedes “there is no settled consensus on the precise contribution of lifestyle… some portion of variation is genetic and stochastic” — but this caveat appears well after the headline claim, not alongside it.
- Blurred evidence tiers in the science chapter: peer-reviewed primary literature (Cell, Nature Aging, JAMA) is cited alongside news commentary and editorials (e.g., a Nature Biotechnology news piece asking “Are GLP-1s the first longevity drugs?”) without visibly distinguishing established findings from speculative framing.
- Survey transparency: the 9,350-respondent, 19-country study underlying the “longevity paradox” finding is described only briefly, with no detail on sampling method, weighting, or margin of error, despite carrying much of the report’s behavioral narrative.
On balance: the report is a useful, clearly organized entry point to the current commercial and scientific landscape, with genuinely extensive sourcing — but it functions more as industry thought-leadership than as a neutral scientific review, and its optimism about timelines and evidence maturity should be weighed against its authors’ commercial stake in the field’s growth.
My own view is that it does not really put much effort in on the science, but it is otherwise quite a good summary even if I agree with Claude about the conflict of interest. (which I do).
As people know I think Aubrey de Grey is good at the science even though I disagree with him about a number of things. Their list of expert is really more about how high profile people are rather than how good their science is.